SPOKANE, WA. – Jubilant HollisterStier Allergy is pleased to announce that it has received zero observations following a recent inspection conducted by the United States Food and Drug Administration, Center for Biologics Evaluation and Research (CBER). This success underscores Jubilant HollisterStier Allergy’s commitment to delivering high-efficacy, safe, and quality allergy extracts and allergenic products in accordance with rigorous industry standards.
The completion of this inspection with no observations is a testament to Jubilant HollisterStier Allergy’s focus on compliance and quality assurance on their mission to elevate allergy. Jubilant HollisterStier Allergy will continue to set a high bar for excellence in allergy immunotherapy, supporting both healthcare providers and the communities they serve.
“Receiving zero observations from CBER is a testament to the diligence and expertise of our team,” said Jerad Holcomb, Vice President of Quality. “We are committed to adhering to the most stringent quality standards, and this reflects in our collective dedication to operational excellence and patient safety.”
“This achievement not only demonstrates Jubilant HollisterStier Allergy’s leadership in quality and compliance, but also reinforces the trust that healthcare providers and their patients have in our capabilities,” said Ben VanGerpen, Chief Scientific Officer. “Our teams are dedicated to continous improvement to meet the evolving regulatory requirements and maintain the highest standards of excellence.”
This achievement reinforces Jubilant HollisterStier Allergy’s role as a trusted partner in the allergy care community.
About Jubilant HollisterStier Allergy:
Jubilant HollisterStier Allergy, a division of Jubilant Pharmova, has been a leading force in the allergenic extract industry for over 100 years. Jubilant HollisterStier Allergy is dedicated to innovation and serving the needs of healthcare providers and patients in the allergy industry.
